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ABSTRACT
Development of RNA interference-based therapies with appropriate therapeutic window remains a
challenge for advanced cancers. Because cancer stem cells (CSC) are responsible of sustaining the
metastatic spread of the disease to distal organs and the progressive gain of resistance of advanced
cancers, new anticancer therapies should be validated specifically for this subpopulation of cells. A
new amphihilic-based gene delivery system that combines PluronicVR F127 micelles with polyplexes
spontaneously formed by electrostatic interaction between anionic siRNA and cationic polyethyleni-
mine (PEI) 10K, was designed (PM). Resultant PM gather the requirements for an efficient and safe
transport of siRNA in terms of its physicochemical characteristics, internalization capacity, toxicity pro-
file and silencing efficacy. PM were loaded with a siRNA against AKT2, an important oncogene involved
in breast cancer tumorigenesis, with a special role in CSC malignancy. Efficacy of siAKT2-PM was vali-
dated in CSC isolated from two breast cancer cell lines: MCF-7 and Triple Negative MDA-MB-231 corre-
sponding to an aggressive subtype of breast cancer. In both cases, we observed significant reduction
on cell invasion capacity and strong inhibition of mammosphere formation after treatment. These
results prompt AKT2 inhibition as a powerful therapeutic target against CSC and pave the way to the
appearance of more effective nanomedicine-based gene therapies aimed to prevent CSC-related
tumor recurrence.
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Introduction
Over the last years, accumulating evidence suggest that can-
cer dormancy and metastatic spread are sustained by the
presence of a discrete population of cells with stem cell
properties such as self-renewal and differentiation capacity
(Dean et al., 2005; Charafe-Jauffret et al., 2009; Lagadec et al.,
2010; Yu et al., 2012). These cells, known as CSC or tumor ini-
tiating cells present specific biological traits responsible for
their resistance to conventional chemotherapeutic drugs, pro-
moting tumor recurrence and metastatic spread. The greatest
challenges in clinical practice, nowadays. Alternative thera-
peutic approaches have raised deep interest in the field, in
particular, gene therapy and its combination with conven-
tional therapies. RNA interference (RNAi) technology, is one
of the main approaches regarding gene therapy that allows
controlled silencing of a specific gene of interest, reducing
undesirable off-target effects (Kurreck, 2009; Deng et al.,
2014; Videira et al., 2014). In the oncology field, this techno-
logy brings the possibility to target oncogenes involved in
proliferation, angiogenesis, metastasis, apoptosis and drug
resistance, among other oncogenic features.
AKT2, one of the three isoforms of the protein kinases B
(PKB) family highly expressed in breast tumors, is a major
downstream effector of the canonical phosphatidylinositol
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3-kinase (PI3-K) pathway which appears generally associated
with acquisition of a malignant phenotype in cancer cells,
and also associated with CSC tumorigenicity (Cheng et al.,
2007, 2008; Umemura et al., 2014; Rafael et al., 2015).
Therefore, silencing of AKT2 through siRNA could be a prom-
ising strategy to impair tumor development and recurrence.
The main challenges related to siRNA-based therapies are
the rapid degradation of siRNA by serum nucleases and their
poor cellular uptake (Rafael et al., 2014). In this context, siRNA
delivery through nanostructured nonviral vectors is a promising
approach that enhances siRNA stability within the bloodstream
and allows the therapeutic nucleic acid to reach the cytoplasm
(Videira et al., 2014; Rafael et al., 2014). Different types of non-
viral systems for siRNA delivery have been proposed, many of
them based on cationic polymers like PEI (Pathak et al., 2009;
Shim & Kwon, 2010). The in vitro and in vivo high transfection
efficiencies observed with PEI-based vectors have been related
to their ability to promote endosomal osmotic swelling and
rupture. The release of the genetic material into the cytoplasm,
avoids its traffic and degradation into the lysosomal compart-
ment (Akinc et al., 2005; Aigner, 2006; Zhang et al., 2007;
Ozpolat et al., 2010, Martin et al., 2012). Unfortunately, PEI pol-
yplexes cannot be used in vivo as a drug delivery system per
se. PEI high cationic charge density renders instability and toxic
side effects such as, membrane damage, interaction with blood
cells and activation of the complement system (Akinc et al.,
2005; Tros de Ilarduya et al., 2010; Roesler et al., 2011; Martin
et al., 2012). In order to overcome PEI-associated drawbacks,
many different strategies have been explored, being PEI graft-
ing with poly(ethylene glycol) (PEG) one of the preferred ones
(Malek et al., 2008; Oskuee et al., 2010).
Here, we proposed the development of PM based on the
combination of PEI with PluronicVR amphiphilic copolymers.
These polymers consist of ethylene oxide (EO) and propylene
oxide (PO) chains arranged in a triblock structure (EOa-POb-
EOa), which are already approved as excipients for many
pharmaceutical applications (Moghimi & Hunter, 2000; Kabanov
et al., 2002). The choice of these polymers relies on their recog-
nized ability to enhance the efficiency of transfection of genetic
material, and their capacity to produce micelles with small sizes
and with a PEGylated surface, which in turn offers stealth prop-
erties to the system, among other advantages (Kabanov et al.,
2005). The main goal of this work is the development of PM
for the efficient and safe delivery of siAKT2 into CSC subpopula-
tions, isolated according to an in vitro CSC model based on the
isolation and tracking of CSC by differential fluorescence emis-
sion, previously developed in our group (Gener et al., 2015).
Our data show strong inhibitory effects on AKT2 mediated by
triblock structured PM in CSC populations, and impairment of
CSC migration and invasion tumorigenic properties in both tri-
ple negative and non-triple negative breast cancer cells.
Material and methods
Production and characterization of polymeric micelles
for siRNA delivery
First, PEI-siRNA complexes were prepared by adding either
10 K or 25 K PEI (Alfa Aesar, Thermo Fisher GmbH, Karlsruhe,
Germany) aqueous solution dropwise to an equal volume of
siRNA aqueous solution, followed by 10 s vortex mixing
before incubation at room temperature, for 30min. The
siRNA-GFP positive and negative control were from Life
Technologies Ltd., Madrid, Spain, and the ones regarding
AKT2 were designed by Shanghai Gene Pharma (Shanghai,
China). Sense siAKT2 sequence used was 50-
GCUCCUUCAUUGGGUACAATT-30, while a nonspecific
sequence 50-UUCUCCGAACGUGUCACGUTT-30 was used as
control (siControl). The PEI-siRNA complexes were selected





Mass per charge of PEI ¼43 gmolð Þ
Mass of siRNA
Mass per charge of phosphate ¼330 gmolð Þ
(1)
Subsequently, PM were prepared using the thin-film
hydration technique (Andrade et al., 2015b). Briefly, the poly-
mer (PluronicVR F68, F108 and F127 kindly provided by BASF,
Ludwigshafen, Germany) was individually weighted and dis-
solved in a mixture of methanol:ethanol (1:1) (Sigma-Aldrich,
Spain). Solvent was removed under vacuum in a rotary evap-
orator and the formed film was left to dry overnight at room
temperature to eliminate any remaining solvent. The film
was then hydrated with previously prepared polyplexes and
vortexed during 1min, into a final 1% (m/v) polymer concen-
tration (Supplementary Figure S1). The obtained dispersion
was filtered through a 0.22-lm syringe filter for sterilization
and to remove eventual aggregates. For the in vivo extrava-
sation studies, DiR fluorochrome (Thermo Fisher GmbH,
Karlsruhe, Germany) was added to the methanol:ethanol
polymer solution at a concentration of 1.5% (percentage in
respect to polymer) (DiR-PM). All the process was the same
as for PM-loaded with polyplexes.
PM’ mean hydrodynamic diameter (md) and polydispersity
index (Pdi) were measured in water by dynamic light scatter-
ing (DLS), and zeta potential was assessed by laser doppler
micro-electrophoresis using a NanoZS (Malvern Instruments,
UK) with an angle of 173˚. The morphology of PM was
assessed by transmission electron microscopy (TEM). For that,
samples were placed on a grid, treated with uranil acetate,
and then observed in a JEM-1210 Transmission Electron
Microscope (JEOL Ltd., Japan) operating at 120KV.
Encapsulation efficiency was assessed by quantification of
the free siRNA in filtrates using UV-Vis spectrophotometer
(Nanodrop 2000, Thermo Fisher GmbH, Karlsruhe, Germany),
after filtration of the formulations by centrifugation, for
10min at 10,000 rpm and 4 C, using 10-K pore filters
(NanosepVR Centrifugal Devices, Pall Corporation, USA). In
addition, gel electrophoresis, using 1% agarose gel, was per-
formed to evaluate siRNA condensation.
The osmolality of formulations was determined at room
temperature using a Micro-Osmometer M3320 (Advanced
Instruments, Inc., USA).
Stability and toxicity studies
In order to study PM stability in serum and to predict their
aggregation pattern in vivo, medium containing a
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concentration of FBS 50% was prepared. PM were incubated
with medium-FBS (50%) and samples collected at different
time-points (0, 4, 6, 12 and 24 h) for DLS measurement. The
cytotoxicity of siRNA-PM was evaluated by MTT assay in vitro
(Supplementary Information S1) and Maximum Tolerated
Dose (MTD) was determined in vivo (Supplementary
Information S2).
Efficacy studies (GFP reporter gene assays)
First, MDA-MB-231 cells expressing GFP were used to assess
the micelles silencing efficacy (Supplementary Information
S3). PM prepared using a siRNA against GFP were added to
the cells at a concentration of 5 104 cells/ml in 96 well
plates, to obtain a final concentration of 200 nM of siRNA per
well. As a positive control, we used cells transfected with
complexes formed between LipofectamineVR 2000 and siRNA
against GFP prepared accordingly to supplier’s instructions.
Cells transfected with PM prepared with a control random
siRNA sequence (siControl), were used as negative control.
The intracellular expression of GFP after transfection was
assessed at 24, 48 or 72 h through different techniques,
according to the experiment (Supplementary Information S4).
Functional studies of siRNA-PM in CSC
To evaluate PM in the subpopulation of CSC, two CSC in vitro
models from breast tumor cell lines (MCF7-
ALDH1A1:tdTomato, MDA-MB-231-ALDH1A1:tdTomato), previ-
ously developed in our laboratory were employed (Gener
et al., 2015) (Supplementary Information S3). Both cell lines
stably expressed an ALDH1A1/tdTomato reporter vector.
Consequently, CSC expressed tdTomato (red fluorescence)
driven by the CSC specific promoter (ALDH1A1), while non-
CSC did not show tdTomato fluorescence (Gener et al., 2015).
This system offered a permanent CSC tagging which per-
mitted the identification and separation of CSC from hetero-
geneous populations, as well as allowed monitoring of CSC
sensitivity in situ within tumor cell population. The CSC
nature of tdTomatoþ cells was previously confirmed by
expression of stemness markers, tumorspheres formation and
high in vivo tumorigenic capacity (Gener et al., 2015).
(a) PM internalization
Unsorted MCF7-ALDH1A1:tdTomato, and MDA-MB-231-
ALDH1A1:tdTomato cells, with high content of CSC (50%)
were used for internalization studies. PM uptake was
assessed by flow cytometry (Fortessa, BD Biosciences)
(Supplementary Information S5). PM for internalization stud-
ies were prepared using 5-DTAF-fluorescentely labeled poly-
mer F127 (Supplementary Information S5).
(b) siAKT2-PM silencing efficacy and its biological effect
onto CSC
To assess silencing efficacy of siAKT2 and its effect on main
CSC malignant characteristics such as transformation and
invasion capacity, CSC from both in vitro CSC models were
sorted by FACS (FACSAria, BD Biosciences) (Supplementary
Information S6). To ensure sample purity, we verified
stemness gene expression profile (ALDH1A1, NANAOG, OCT4,
NOTCH4, CXCR1, CXCR4, CD133, CD44, CD24) of isolated CSC
after each sorting.
CSC were transfected with PM prepared using the siAKT2
and siControl to obtain a final concentration of 200 nM of
siRNA per well. Silencing efficacy of siAKT2-PM in CSC was
quantified at 72-h post-transfection using quantitative PCR
(qPCR) (Supplementary Information S7).
Anchorage independent growth of CSC was assessed by
CytoSelectTM Cell Transformation Assay Kit (Cell Biolabs).
A semisolid agar media were prepared according to man-
ufacturer’s instructions, and PM-siAKT2 and PM-siControl
were alternatively added to each well. After 6–8 days of incu-
bation, colonies were observed under optical microscope and
viable transformed cells counted, using trypan blue. Invasive
potential of sorted CSC was assessed using CytoSelectTM
Laminin Cell Invasion Assay Kit (Cell Biolabs) (Supplementary
Information S8).
In vivo behavior of siRNA-PM
In vivo visualization of DiR-PM was performed using a fibered
confocal fluorescence microscopy (FCFM) imaging system
(CellvizioVR Dual Band, Mauna Kea Technologies, Paris, France)
in patient derived tumor xenografts (PDX). Pancreatic tumor
samples were obtained from Dr. Manuel Hidalgo’s laboratory
and implanted subcutaneously in athymic mice, following
previously stablished methods (Martinez-Garcia et al., 2014),
under the approval of Vall d’Hebron Animal Ethics
Committee. PDX-bearing athymic mice were injected via a
tail vein with DiR with labeled PM (1.5% DiR in respect to
F127 in the PM). FITC-Dextran (MW 150,000 kDa, 500mg/kg,
150 lL) was injected intravenously immediately prior to FCFM
imaging to visualize the microvascular network. A small inci-
sion (0.5 cm) was made on tumor (n¼ 4) and abdominal
wall to insert the laser probe. During the time of acquisition,
mice were placed in the prone position (for tumor imaging)
or supine position (for peritoneum and liver imaging) and
anesthetized with 1.5% isoflurane. Images and videos were
acquired using an S-1500 probe. Extravasation of the DiR-PM
through blood vessel wall and accumulation over time were
assessed in tumor, liver and peritoneum at 0.5 and 4 h post-
injection. All imaging was carried out using a frame rate of
9 Hz, a field of view of 618 Å 609 lm and 100% laser power
at 488 and 660 nm. Images and videos were analyzed using
CellvizioVR Dual viewer (Mauna Kea Technologies,
Paris, France).
Statistical analysis
At least three batches of each PM were produced and char-
acterized. Results were expressed as mean± SD. For bio-
logical studies, at least three replicates, each involving at
least two technical replicates, were involved in final results
expressed as the mean± SD. Unpaired Student’s t-test was
used to determine p Values. Differences were regarded as
statistically significant when p Value was smaller than .05.
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Results
Effective siRNA delivery of F127 and PEI 10k based PM
In order to develop an efficient and safe siRNA delivery sys-
tem, we prepared PluronicVR -based empty micelles using dif-
ferent polymers (PluronicVR F68, F108 and F127). The micelles
presented a size lower than 150 nm (inferior to 50 nm for
PluronicVR F108 and F127) and near neutral surface charge
(Figure 1(A)). Polymer F68 was discarded from further studies
due to the high polydispersity of micelles and the low repro-
ducibility obtained (Figure 1(A)). Cytotoxicity assessment was
then performed using F127 and F108 polymers
(Supplementary Figure S2). Both PluronicVR F108 and F127
presented an IC50 superior to 10mg/ml, but since Pluronic
VR
F127 originates micelles presenting the lowest values of md
and a less polydispersed population, this polymer was
chosen for the production of micelles combined with PEI-
based polyplexes. Two types of branched PEI (10 K and 25K),
as well as different PEI:siRNA N/P ratios (25 and 50) were
tested. The formulations composed by PEI:siRNA polyplexes
of N/P ratio 50 presented higher transfection rates than poly-
plexes at lower N/P ratios (Figure 1(B)). In the assessment of
the biological efficacy, no significant differences were
observed between both types of PEI (Figure 1(B)), but since
the 10 K branched PEI, its known to exhibit a significant
lower toxicity profile (Symonds et al., 2005; Paul et al., 2014),
it was chosen for further studies. The presence of 1%
PluronicVR in the form of micelles improved significantly the
transfection efficiency of the polyplexes as observed both quan-
titatively and qualitatively by an increased inhibition of gene
expression (Figure 1(B,C)). PluronicVR F127 micelles encapsulat-
ing PEI 10K:siRNA polyplexes at a N/P ratio 50 gathered the
most promising features for further successful applications.
Therefore, we proceeded to extensively characterize this formu-
lation in terms of its size, Pdi, zeta potential, serum stability,
entrapment efficiency, cytotoxicity, and internalization profile.
The combination of poloxamer F127 and 10 K branched
PEI-based polyplexes originated particles with ideal character-
istics for siRNA delivery and intravenous administration. The
micelles presented a mean diameter of 26 nm, both for
loaded and unloaded formulations, and low polydispersity
indexes ( 0.2). Despite the positive charges associated with
PEI, micelles present a neutral charge mainly caused by the
presence of PEG at their surface. Moreover, the micelles pre-
sent an osmolarity value slightly superior to PBS but <350
mOsm/Kg, which corroborates an adequate applicability for
systemic administration (Figure 2(A)). Mean diameter values
as well as low polydispersity, were also confirmed by TEM
images, where it is possible to observe micelles of small size
and spherical characteristic morphology (Figure 2(B)).
Figure 1. Selection of PluronicVR , combined with the PEI-based polyplexes, for the production of micelles. (A) Poly(ethylene glycol) (PEG), polypropylene oxide units
(PPO) and critical micelle concentration (CMC) values of the different PluronicVR used (according to the manufacturer) and the physicochemical characterization (size,
polydispersity, surface charge) of the resulting PluronicVR -based micelles. Results are expressed as mean± SD, n¼ 3. (B) Differences on the intensity of GFP in GFP
expressing RXO-C cells upon incubation with PEI-siRNA polyplexes and PEI-siRNA-PluronicVR micelles (obtained by direct dissolution method). Silencing efficacy
reached by LipofectaminVR 2000 was used as gold standard for normalization of the results. Results are expressed as mean ± sd (n 3). p .05 compared to the
polyplexes without PluronicV
R
F127. (C) Fluorescent microscopy photographs confirming the GFP silencing efficacy of the selected formulation for siGFP delivery. No
gene inhibition was observed in cells transfected with siControl sequence (siC).
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In order to confirm if the siRNA was correctly complexed
with PEI and associated with micelles (PM-siRNA), the entrap-
ment efficiency was determined by two distinct methods.
The indirect method that measures free siRNA concentration
at the supernatant after PM centrifugation with filtration
showed entrapment efficiencies higher than 96% (Figure 2(C)).
Additionally, no free siRNA fraction was detectable by agarose
gel retardation assay in PM-siRNA samples (Figure 2(D)).
Complete PM internalization within 4 h of incubation
Internalization of fluorescent-labeled micelles was assessed
quantitatively by flow cytometry (Figure 3(A,B)) and qualita-
tively by confocal microscopy (Figure 3(C)). In order to study
the uptake profile, cells were incubated with 5-DTAF labeled
PM at different time-points. With the objective to check if
there is any difference in the internalization pattern between
CSC and non-CSC, MDA-MB-231-ALDH1A1:tdTomato and
MCF-7-ALDH1A1:tdTomato cells with 50% of tdTomatoþ
(CSC) were used. We observed 90% of PM internalization at
4 h after incubation (Figure 3(A)). Interestingly, although no
significant differences were observed between CSC and non-
CSC cells regarding the amount of cells that internalize
micelles, superior values of fluorescence intensity for CSC
cells were detected, which represents a higher number of PM
inside each cell (Figure 3(B)). For qualitative analysis, MDA-
MB-231 cells were incubated during 4 h with micelles carry-
ing a fluorescent-labeled siRNA (siRNA-AlexaFluor 488) and
observed by confocal microscopy. As expected, complete
internalization of micelles is observed after the incubation
time. In confocal microscopy images it was also possible to
see that green-labeled siRNA was not co-localized with endo-
somal vesicles, but already available at the cytoplasm, where
its effects are exerted (Figure 3(C)).
PM do not present in vitro or in vivo toxicity
Effects on cell viability (IC50) of PM with loaded polyplexes
as well as of their isolated components were assessed in vitro
via MTT assay in both, MDA-MB-231 and MCF-7 parental
breast cancer cells (Figure 4(A)). As observed in both, dose-
effect plots and IC50 values, F127 did not cause significant
toxicity to the cells. On the contrary, PEI alone was highly
toxic. Interestingly, PEI-related toxicity appears to be reduced
when it is complexed with negatively charged siRNA, and
even more reduced in the presence of the F127 shell. The
fact that PM concentration showing efficacy in vitro (5mg/
ml) is inferior to their IC50 value, suggests that PM will not
significantly cause toxicity after administration.
Prior to in vivo administration of PM, a serum stability
assay was performed in order to predict the degree of inter-
action and aggregation between PM and serum components.
Mean size distribution curves demonstrated aggregation of
PM with serum components over time, since a reduction of
the medium particles fraction (20–100 nm) with a consequent
increase in the percentage of particles with higher sizes
(>100 nm), could be observed. This behavior was especially
remarkable after 12 h of incubation. Taking into account that
Formulation [siRNA] ng/µl
siRNA solution 8.23 ± 0.15
Concentrated Micelles 8.17 ± 0.31
Micelles Supernatant 0.26 ± 0.11


















Md ± sd 
(nm)
Pdi ± sd Z ± sd (mV)
Osmolarity ± sd 
(mOsm/kg)
Unloaded 26.93 ± 3.61 0.20 ± 0.08 0.07 ± 0.14 322.67 ± 1.15











Figure 2. Physicochemical characterization of F127 PM for siRNA delivery. (A) Summary of size, polydispersity, zeta potential and osmolarity values of PM. Results
are expressed as mean± sd (n 3). (B) mean hydrodynamic diameter distribution of PM-siControl represented trough the graph of size dispersion by intensity
together with TEM images of PM at different magnifications. Scale bar represents 100 nm and 50 nm, respectively. (C) siRNA entrapment efficient determined by a
spectrophotometer method. Results are expressed as mean± sd (n 3). (D) siRNA entrapment efficient determined by agarose gel retardation assay.
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PM generally present a serum half-life inferior to 12 h, the
observed aggregation does not seem to constitute a major
problem for an intravenous administration of the formulation
(Supplementary Figure S3A).
Safety of PM was then assessed in vivo. For this, PM were
administered to healthy mice at increasing concentrations in
order to determine the Maximum Tolerated Dose (MTD). The
maximum administrated dose of 80mg of PM per kg of body
weight was well tolerated, without inducing adverse side
effects up to 12 days post-administration (Supplementary
Figure S3B). No significant changes in weight were seen in
animals treated with PM when compared to a control group
of animals injected with PBS (p .05) (Figure 4(B)).
PM-siAKT2 reduce the metastatic potential of CSC
PM entrapping a siRNA against GFP were incubated at differ-
ent times with GFP expressing MDA-MB-231 breast cancer
cells. A clear reduction of GFP expression was observed 24 h
post-transfection in cells treated with GFP-siRNA when com-
pared with cells transfected with control siRNA (siControl)
(Figure 5(A,B)). Furthermore, PM-associated GFP reduction
was higher than with positive control LipofectamineVR 2000.
Next, we examined whether PM could be used to silence
a potential therapeutic target of breast CSC. PM were pre-
pared using either siAKT2 or siControl and transfected into
MDA-MB-231-ALDH1A1:tdTomato and MCF-7-ALDH1A1:td
Tomato breast CSC isolated fractions. A strong decrease of
AKT2 expression was confirmed by qPCR in both cell lines
(Figure 6(A)). Subsequently, in order to determine the conse-
quences related to AKT2 inhibition in the CSC fraction, cell
invasion and anchorage independent growth ability were
assessed. Regarding the invasive potential of CSC, invasive-
ness was significantly reduced in both cell lines after PM-
siAKT2 transfection (Figure 6(B)). Further, we also observed
that the number of transformed cells were significantly
reduced and accentuated impairment of colonies formation
was additionally observed (Figure 6(C)).
PM-siAKT2 extravasate into clinically relevant
tumor models
In order to evaluate the in vivo behavior of PM-siAKT nano-
particles, we studied the blood circulation and tumor extrava-
sation of PM labeled with DiR near-infrared fluorochrome by
fibered confocal fluorescence microscopy (FCFM) imaging.
Figure 3. Internalization profile of PM. (A,B) FACS quantification of micelles uptake by MDA-MB-231 and MCF-7 ALDH1A1 tdTomato positive vs. negative cells. The
cells were incubated with the 5-DTAF labeled PM and the percentage of cells emitting green fluorescence (A) as well as the intensity of fluorescence (B) was quanti-
fied at different time-points. Results are expressed as mean ± sd (n¼ 3), p .01 for de comparison between CSC and non-CSC. (C) Confocal Microscopy analysis
of particles internalization containing a fluorescent siRNA (siRNA-AlexaFluor 488). The arrow illustrates the respective intracellular distribution of nanoparticle and
Lysotracker DND-99. Note: For better comprehension of the image please visualize the online version of the manuscript.
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As a tumor model we choose to work with patient derived
tumors, since vascularity, stroma and gene expression profiles
of PDX are more similar to the original primary tumor than
conventional xenograft models using established cancer cell
lines (Martinez-Garcia et al., 2014). Results indicate that PM
can be seen in circulation immediately after administration,
but also 4 h post-administration (Figure 7). Interestingly, PM
and the agent labeling the vasculature (FITC-Dextran) are
also seen outside the vascular vessels 4 h post-administration,
probably due to the vascular permeability in tumors. Such
extravasation is not seen in other vessels of the mice, such
the ones in the peritoneum (Supplementary Figure S4).
Overall, our results indicate that PM-siRNA nanosystem is
stable in circulation at least for 4 h and reaches the tumor
parenchyma efficiently.
Discussion
In this work PM were chosen as siRNA delivery systems due
to their well-known versatility to produce systems presenting
long blood-circulating profiles and able to improve the cellu-
lar uptake and the therapeutic efficacy of the encapsulated
compounds (Andrade et al., 2011; Andrade et al., 2013). From
a broad range of amphiphilic polymers used to produce
micelles, poloxamers enjoy special prominence due to their
biocompatible and biodegradable nature, well-established
Figure 4. In vitro and in vivo toxicity of PM. (A) Assessment of the effects of PM and isolated components concentration in vitro. IC50 values for each component
and for PM. The values were obtained by interpolation of y¼ 50 from the dose-effect curves fit using the real concentrations used for each sample. Results are
expressed as mean ± sd (n¼ 3). (B) In vivo the PM did not show any toxicity. In the graph is presented the body weigh variation of animals up to 12 days postadmi-
nistration of the samples. Results are expressed as mean ± sd (n¼ 3).
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status as drug delivery and biomedical excipients, and cap-
acity to improve the transfection of genetic material
(Kabanov et al., 2005; Chen et al., 2015; Yang et al., 2008).
Different PluronicVR (F68, F108, F127) were tested, being
the PluronicVR F127 selected due to its better technological
features (Figure 1(A)). The smaller size and Pdi of F127-based
micelles can be explained by its lower CMC, hydrophilic-lipo-
philic balance (HLB) and CMT (24 C for 1% w/v (Andrade
et al., 2015b; Andrade et al., 2015a)), whereas F68 presents
the higher CMC and CMT (54–56.21 C for 1% w/v (Lin &
Alexandridis, 2002)) and consequently higher diameter. The
same behavior was observed previously (Tsui et al., 2010).
Since poloxamers present neutral charge at the physiological
pH, it was necessary to introduce a cationic component to
the formulation in order to obtain the required positive
charge to complex the anionic siRNA. Thus, the branched PEI
10 K was chosen as polycation to produce the polyplexes
(Supplementary Figure 1(B,C)).
Other research groups developed micellar systems for
siRNA delivery proving the utility of this type of systems.
However, contrary to the complex chemical modifications
proposed by other studies (Wen et al., 2010; Buchman et al.,
Figure 5. GFP reporter assay for PM biological efficacy assessment. (A) Fluorescent images of MDA-MB-231/GFP cells were taken 24, 48 and 72 h after incubation
with PM-siGFP and PM-siControl. (B) Time-lapse experiment in which fluorescent images was captured each 30min during the 72 h period of incubation of the
same cells with siGFP and siControl associated with PM or LipofectamineVR 2000. The values represent the fluorescent intensity detected for each time-point. Results
are expressed as mean ± sd (n¼ 3), p .001 for the comparison between PM-siGFP and Lipofectamine-siGFP. LipofectamineVR 2000 is represented as Lipo.
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2013); in this work, we propose a simple association of PEI-
based polyplexes with PluronicVR F127 based PM.
Noteworthy, our system gathers well known advantages
of PM, combined with additional benefits of both PEI and
poloxamers in terms of enhanced gene transfection effi-
ciency. Comparing the silencing efficacy of PEI polyplexes
with the PM formed from the combination of PEI and F127,
it is possible to observe that the presence of PluronicVR F127
significantly increase biological efficacy (Figure 1(B)). This
result can be explained by the reported capacity of polox-
amers to enhance the transfection efficiency of genetic
material. Although not completely understood and explained,
poloxamers present the capacity to interfere to some extent
with cell membranes reducing its structure and microviscos-
ity/fluidity (Williford et al., 2014; Iyer et al., 2014). Further,
they also improve endosomal compartment escape via mem-
brane disruption and pore formation (Batrakova et al., 2003b;
Demina et al., 2005). Moreover, poloxamers with an inter-
mediate HLB value like F127 (HLB ¼18–23), have shown
higher ability to interfere with membranes than poloxamers
with higher HLB like F68 and F108 (HLB> 24) (Chen et al.,
2015). In addition, the physicochemical characterization of
the final system shows micelles with spherical shape and md
close to 20 nm, corroborated by DLS and TEM (Figure 2(A,B)).
Also, the formulation offers high capacity to complex siRNA
(Figure 2(C,D)). Internalization studies demonstrated that
micelles are able to be taken up by cells and escape from
the endosomes, releasing the genetic material to the cyto-
plasm (Figure 3(C)). This result is in agreement with the bio-
logical efficacy seen using a GFP reporter gene (Figure 5)
and with the silencing of the AKT2 (Figure 6), since internal-
ization of polyplexes/micelles containing siRNA is the first
step to enable its intracellular biological performance.
Moreover, our system does not present significant toxicity
both in vitro (Figure 4(A)) and in vivo (Figure 4(B) and
Supplementary Figure S3B). This might be related to the
aforementioned biocompatibility associated with this poly-
mers (Jung et al., 2010; Diniz et al., 2015). Another advantage
about the presence of poloxamers in the formulation was evi-
denced by serum stability assays (Supplementary Figure S3A).
Figure 6. PM-siAKT2 effects in MDA-MB-231 and MCF-7 CSC. (A): The reduction of AKT2 gene expression was detected in both cell lines through qPCR. The pre-
sented values are normalized to the housekeeping genes (Actin and GADPH). (B) Quantification of the number of invasive cells after incubation with PM-siAKT2 vs.
PM-siC. (C) Quantification of the number of transformed cells after incubation with PM-siAKT2 vs. PM-siC. Colonies formation on the soft agar after incubation of
cells with PM-siAKT2 vs. PM-siC. Results are expressed as mean ± sd (n¼ 3), p .001 for the comparison between PM-siC and PM-siAKT2. siControl is repre-
sented as siC.
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Our results showed that there is no aggregation with serum
components up to 12 h of incubation, suggesting that this
PM may be adequate for intravenous administration in vivo,
since as for other micellar systems, a circulation half-life
under 12 h is expected (Rijcken et al., 2007). Moreover, our
results with in vivo FCFM imaging show that PM can be
observed in circulation up to 4 h postadministration and that
nanosystems are able to leave the vascular bed and extrava-
sate into the tumor parenchyma, probably due to the pres-
ence of leaky vasculature of the tumors, as previously
demonstrated by FCFM technique in animal models (Bai
et al., 2016). This process would ensure the enhanced perme-
ability and retention (EPR) effect (Matsumura & Maeda, 1986;
Maeda et al., 2000) and would help to increase the efficacy
of the siRNA.
The main objective of this work is the development of a
nanosystem able to deliver a siRNA against the oncogene
AKT2 in CSC subpopulation. Due to their unique phenotype,
CSC are resistant to conventional therapies (Yu et al., 2012;
Dragu et al., 2015). Even though several new promising anti-
cancer treatments have been proposed over the past years,
just few of them were extensively studied for their efficacy
also in the population of CSC. Therefore, it is of major import-
ance to find an adequate target against CSC and an effective
delivery system able to reach them; otherwise the reservoir of
resistant CSC will cause recurrence of aggressive tumor and
metastatic growth overtime (Nandy et al., 2015; Sehl et al.,
2015). In this work, we used a CSC in vitro model based on
tdTomato expression under the control of CSC-specific
ALDH1A1 promoter, in order to study the efficacy of AKT2
silencing in CSC fraction. This CSC model was extensively vali-
dated previously in vitro and in vivo (Gener et al., 2015). After
treatment with PM-siAKT2, the transformation capacity of CSC
fractions (MDA-MB-231 and MCF7) was significantly abolished
(Figure 6(C)). Similarly, the invasion capacity of CSC signifi-
cantly decreased after the transfection with the PM-siAKT2
(Figure 6(B)). These results suggest that AKT2 silencing strat-
egy may be successful as a target for future RNAi-based anti-
tumor therapies particularly on highly aggressive CSC.
Further, the internalization studies performed in MDA-MB-
231-ALDH1A1:tdTomato and MCF-7-ALDH1A1:tdTomato cells
with 50% of tdTomatoþ (CSC) revealed an unexpected signifi-
cant preferential uptake of PM by CSC (Figure 3(A,B)), which
might reinforce its biological efficacy in these subpopulation
of cells. Moreover, by interfering with the cellular membrane,
poloxamers inhibit the ATPase activity and the efflux function
of P-glycoprotein, improving the efficacy of anticancer drugs
(Batrakova et al., 2001; Batrakova et al., 2003a). Therefore, the
mechanism involved in the enhancement of transfection effi-
ciency by poloxamers might also underlie its effects as multi-
drug resistance (MDR) chemosensitizers. In addition, it has also
been shown that poloxamers interfere with mitochondrial
function showing to enhance proapoptotic signaling and
decrease tumorigenicity of cancer cells by altering the epigen-
etic regulation of cells mainly in MDR over non-MDR cells
(Minko et al., 2005; Alakhova et al., 2010; Alakhova et al.,
2013). Taking into account that CSC display some of the char-
acteristics of MDR cells, like overexpression of efflux systems,
it is expected that poloxamers present the capacity to:
(i) enhance the anticancer activity of drugs, (ii) increase the
Figure 7. In vivo behavior of PM-siAKT2 in tumors. Real time fibered confocal fluorescence microscopic (FCFM) images of mice administered with DiR labeled PM.
Images correspond to representative single frame of live FCFM imaging of tumors of mice administered 30min prior to imaging (half the dose of DiR-PM) and 4 h
before imaging (full dose of DiR-PM). Vasculature was visualized using FITC-Dextran (500mg/kg). Signal corresponding to DiR-labeled PM is mainly localized into
the vessels 30-min post-administration (see arrows), while the DiR signal is more dispersed and distributed 4-h post-administration (asterisk), clearly showing that
the PM extravasated from the vessels invading the tumoral parenchyma. Note: For better comprehension of the image please visualize the online version of
the manuscript.
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transfection efficiency of OGN, and (iii) decrease the tumori-
genicity and aggressiveness of CSC (Alakhova et al., 2013).
Conclusions
In this study, an innovative nanocarrier system composed by
PluronicVR F127-based micelles associated with PEI-based pol-
yplexes has been developed with the objective to overcome
the major drawbacks associated to the genetic material deliv-
ery systems, namely siRNA degradation, insufficient transfec-
tion efficiency or excessive nanoparticles-related toxicity. The
tri-block system generated gathers the requirements for an
efficient and safe transport of siRNA in terms of physico-
chemical characteristics, internalization capacity into CSC
population, biological efficacy and toxicity profile. Moreover,
we also observed a reduction of the invasion and transform-
ation capacities of breast cancer cells, when transfected with
PM entrapping polyplexes with siRNA against AKT2 as a gene
of interest, with significant positive results observed mainly
in triple negative highly malignant and resistant CSC popula-
tion. The obtained results suggest that this new formulation
could serve as an efficient technological platform for siRNA
delivery, and a step forward in gene therapy against CSC
subpopulations.
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